Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension

Arthritis and Rheumatology

Volumn 68, Issue 4, 2016, Pages 1004-1012

  Antoniou, K M ^a,b   Margaritopoulos, G A ^a,b   Goh, N S ^a   Karagiannis, K ^a   Desai, S R ^c   Nicholson, A G ^a   Siafakas, N M ^b   Coghlan, J G ^d   Denton, C P ^d   Hansell, D M ^a   Wells, A U ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE;

ADULT; ARTICLE; COMBINED PULMONARY FIBROSIS AND EMPHYSEMA; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GAS DIFFUSION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLERODERMA; SCREENING TEST; SMOKING; AGED; COHORT ANALYSIS; COMPLICATION; DIAGNOSTIC IMAGING; EPIDEMIOLOGY; HYPERTENSION, PULMONARY; LUNG; LUNG DISEASES, INTERSTITIAL; MASS SCREENING; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS; RETROSPECTIVE STUDY; SCLERODERMA, SYSTEMIC; VITAL CAPACITY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); ECHOCARDIOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERTENSION, PULMONARY; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PULMONARY DIFFUSING CAPACITY; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84962053233     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39528     Document Type: Article

References (37)

1. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM., Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009; 33: 882-96.
2. Wells AU, Margaritopoulos GA, Antoniou KM, Denton C., Interstitial lung disease in systemic sclerosis. Semin Respir Crit Care Med 2014; 35: 213-21.
3. Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM, et al., Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40: 1229-36.
4. Steen VD, Lucas M, Fertig N, Medsger TA Jr., Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol 2007; 34: 2230-5.
5. Steen VD, Chou M, Shanmugam V, Mathias M, Kuru T, Morrissey R., Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest 2008; 134: 146-51.
6. Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, et al., Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008; 35: 458-65.
7. Launay D, Humbert M, Berezne A, Cottin V, Allanore Y, Couderc LJ, et al., Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 2011; 140: 1016-24.
8. Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, et al,; GERM"O"P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105-11.
9. Cottin V, Nunes H, Mouthon L, Gamondes D, Lazor R, Hachulla E, et al, and the Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 2011; 63: 295-304.
10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
11. Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, et al., Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56: 2005-12.
12. Desai SR, Veeraraghavan S, Hansell DM, Nikolakopolou A, Goh NS, Nicholson AG, et al., CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004; 232: 560-7.
13. Copley SJ, Wells AU, Sivakumaran P, Rubens MB, Lee YC, Desai SR, et al., Asbestosis and idiopathic pulmonary fibrosis: comparison of thin-section CT features. Radiology 2003; 229: 731-6.
14. Antoniou KM, Walsh SL, Hansell DM, Rubens MR, Marten K, Tennant R, et al., Smoking-related emphysema is associated with idiopathic pulmonary fibrosis and rheumatoid lung. Respirology 2013; 18: 1191-6.
15. Wiggins J, Strickland B, Turner-Warwick M., Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 1990; 84: 365-9.
16. Wells AU, Hansell DM, Rubens MB, Cailes JB, Black CM, du Bois RM., Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. Am J Respir Crit Care Med 1997; 155: 1657-64.
17. Akagi T, Matsumoto T, Harada T, Tanaka M, Kuraki T, Fujita M, et al., Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med 2009; 103: 1209-15.
18. Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM., Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997; 155: 1367-75.
19. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al., Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54.
20. Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al., Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52: 155-60.
21. Zisman DA, Karlamangla AS, Kawut SM, Shlobin OA, Saggar R, Ross DJ, et al., Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2008; 133: 640-5.
22. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD., Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131: 657-63.
23. Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al, on behalf of the DETECT Study Group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-9.
24. Vuorinen K, Ohlmeier S, Lepparanta O, Salmenkivi K, Myllarniemi M, Kinnula VL., Peroxiredoxin II expression and its association with oxidative stress and cell proliferation in human idiopathic pulmonary fibrosis. J Histochem Cytochem 2008; 56: 951-9.
25. Volonte D, Kahkonen B, Shapiro S, Di Y, Galbiati F., Caveolin-1 expression is required for the development of pulmonary emphysema through activation of the ATM-p53-p21 pathway. J Biol Chem 2009; 284: 5462-6.
26. Zandvoort A, Postma DS, Jonker MR, Noordhoek JA, Vos JT, Timens W., Smad gene expression in pulmonary fibroblasts: indications for defective ECM repair in COPD. Respir Res 2008; 9: 83.
27. Gauldie J, Kolb M, Ask K, Martin G, Bonniaud P, Warburton D., Smad3 signaling involved in pulmonary fibrosis and emphysema. Proc Am Thorac Soc 2006; 3: 696-702.
28. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L, for the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004; 50: 3085-92.
29. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al, and the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38-46.
30. Bongartz T, Cantaert T, Atkins SR, Harle P, Myers JL, Turesson C, et al., Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 70-5.
31. Greene CM, Low TB, O'Neill SJ, McElvaney NG., Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. Am J Respir Crit Care Med 2010; 181: 31-5.
32. Rinaldi M, Lehouck A, Heulens N, Lavend'homme R, Carlier V, Saint-Remy JM, et al., Antielastin B-cell and T-cell immunity in patients with chronic obstructive pulmonary disease. Thorax 2012; 67: 694-700.
33. Faner R, Rojas M, Macnee W, Agustí A., Abnormal lung aging in chronic obstructive pulmonary diseasedisease and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 306-13.
34. Brusselle GG, Joos GF, Bracke KR., New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378: 1015-26.
35. Marsland BJ, Konigshoff M, Saglani S, Eickelberg O., Immune system dysregulation in chronic lung disease. Eur Respir J 2011; 38: 500-1.
36. Plumb J, Smyth LJ, Adams HR, Vestbo J, Bentley A, Singh SD., Increased T-regulatory cells within lymphocyte follicles in moderate COPD. Eur Respir J 2009; 34: 89-94.
37. Barnes PJ, Celli BR., Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-85.